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Objectives In this study, a meta-analysis of observational studies was performed to compare the
rate of recurrent neurological events (RNE) between transcatheter closure and medical management
of patients with cryptogenic stroke/transient ischemic attack (TIA) and concomitant patent foramen
ovale (PFO).
Background A signiﬁcant controversy surrounds the optimal strategy for treatment of cryptogenic
stroke/TIA and coexistent PFO.
Methods We conducted a MEDLINE search with standard search terms to determine eligible
studies.
Results Adjusted incidence rates of RNE were 0.8 (95% conﬁdence interval [CI]: 0.5 to 1.1) events
and 5.0 (95% CI: 3.6 to 6.9) events/100 person-years (PY) in the transcatheter closure and medical
management arms, respectively. Meta-analysis of the limited number of comparative studies and
meta-regression analysis suggested that the transcatheter closure might be superior to the medical
therapy in prevention of RNE after cryptogenic stroke. Comparison of the anticoagulation and anti-
platelet therapy subgroups of the medical arm yielded a signiﬁcantly lower risk of RNE within pa-
tients treated with anticoagulants. Device-related complications were encountered at the rate of
4.1 (95% CI: 3.2 to 5.0) events/100 PY, with atrial arrhythmias being the most frequent complication.
After transcatheter closure, RNE did not seem to be related to the pre-treatment shunt size or the
presence of residual shunting in the follow-up period. Signiﬁcant beneﬁt of transcatheter PFO clo-
sure was apparent in elderly patients, patients with concomitant atrial septal aneurysm, and patients
with thrombophilia.
Conclusions Rates of RNE with transcatheter closure and medical therapy in patients presenting
with cryptogenic stroke or TIA were estimated at 0.8 and 5.0 events/100 PY. Further randomized
controlled trials are needed to conclusively compare these 2 management strategies. (J Am Coll
Cardiol Intv 2012;5:777–89) © 2012 by the American College of Cardiology Foundation
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778Epidemiological studies have found a prevalence of 44%
to 66% of patent foramen ovale (PFO) in patients with
cryptogenic stroke as compared with 27% in autopsy
series of all-cause deaths (1). The higher prevalence of
PFO in patients with cryptogenic stroke suggests that at
least in some patients with cryptogenic stroke, the cause
of stroke might be paradoxical thromboembolism (PTE).
However, it is important to realize that in many or
possibly most patients with cryptogenic stroke and PFO,
PTE might not be the cause of stroke. Percutaneous
closure has been available for over 10 years with very little
hard evidence to guide patient and device selection. Inves-
tigators have used their own clinical judgment to decide
when and how to percutaneously close PFO. There is 1
multicenter randomized controlled trial (CLOSURE 1
[Evaluation of the STARFlex Septal Closure System in
Patients with a Stroke and/or Transient Ischemic Attack
due to Presumed Paradoxical Embolism through a Patent
Foramen Ovale]) recently reported,
and several trials are ongoing but
with slow recruitment (2).
Although several single-center
experiences indicated reduction
in recurrent neurological events
(RNE) after PFO closure, the
CLOSURE 1 trial failed to dem-
onstrate any significant difference
in RNE with PFO closure com-
pared with medical management
with antiplatelet or anticoagula-
tion therapy. Although the strength
of a randomized trial is to mini-
mize unmeasured biases, entry bias
introduced by preferences of inves-
tigators and patients—especially
when the same therapy is available
utside the clinical trial—can play an important role in the
dequacy of final study population. This is of particular
elevance in this population where the chance of PFO being
n innocent bystander is high. Single-center studies have
ven larger limitations, including small numbers of patients,
eporting bias, and lack of an adequate control population,
o name a few. However, they provide a unique insight to
ur understanding when a relatively rare clinical problem is
nvestigated, and “clinical judgment” is exerted to select the
reatment approach. Therefore, we performed a compre-
ensive meta-analysis of the available observational studies
o evaluate the risk of RNE after transcatheter closure and
edical therapy in patients with cryptogenic stroke/
ransient ischemic attack (TIA) due to presumed paradox-
cal thromboembolism. We specifically focused on patient
election (PFO morphology and age) and complication
ates to better understand the nonrandomized data. Due
Abbreviations
and Acronyms
ASA  atrial septal
aneurysm
CI  confidence interval
PFO  patent foramen ovale
PTE  paradoxical
thromboembolism
PY  person-years
RD  risk difference
RNE  recurrent
neurological events
RR  relative risk
TIA  transient ischemic
attacko scarcity of comparative published data, our meta- cnalysis does not primarily focus on the comparison of
he 2 strategies, because it would be fraught with statis-
ical biases arising from differences in methodology of
ifferent studies.
ethods
Search strategy. We queried Medline, EMBASE, and Co-
hrane databases for eligible studies with the terms “patent
oramen ovale,” “PFO,” “atrial septal aneurysm,” “ASA
ranscatheter closure,” “heart septal defects (atrial),” “inter-
trial shunt,” “recurrent thromboembolism,” “recurrent
troke,” and “recurrent TIA.” We also evaluated studies
eporting the efficacy of transcatheter PFO closure for
ndications other than stroke/TIA to derive comprehensive
ooled estimates for device-related complications and post-
rocedure residual shunting.
Study characteristics. We considered all observational stud-
ies, including prospective or retrospective cohort studies,
case series, and comparative studies. Case series reporting
outcomes after transcatheter closure with at least 100
patients were included. Comparative studies comparing
transcatheter closure and medical therapy or case series
reporting outcomes after medical management were in-
cluded, regardless of the sample size. Studies reporting
recurrent stroke or TIA after transcatheter PFO closure or
medical management of presumed PTE through PFO were
included for analysis. We excluded studies that reported
composite outcomes for atrial septal defects along with
PFO, unless it was possible to clearly determine the out-
comes of PFO closure. In cases of research groups reporting
cumulative results in multiple publications, caution was
exercised in data extraction, and only studies with the largest
sample size and follow-up period for each outcome were
included.
Outcome measures. Primary outcome was defined as recur-
ent stroke or TIA in the follow-up period. We analyzed the
econdary outcomes of procedural failures, device-related
omplications, and residual shunting post-procedure. We
onducted several subgroup analyses to best define the
evice and patient characteristics that might govern the
ccurrence of RNE in follow-up period. These included
omparison of RNE among old versus young, PFO alone
ersus PFO with concomitant atrial septal aneurysm (ASA),
ntiplatelet versus anticoagulant therapies, and the effect of
hrombophilia.
Meta-analysis. Meta-analysis was carried out with the
“metan” function in Stata (version 10.0, StataCorp, College
Station, Texas). Fixed effects modeling was primarily used
to conduct outcomes meta-analysis from included stud-
ies. Random effects modeling was used in case of signif-
icant statistical heterogeneity (I2 50% with p  0.05).
ublication biases were assessed separately for the trans-
atheter closure and the medical therapy arms, with the
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 7 , 2 0 1 2 Agarwal et al.
J U L Y 2 0 1 2 : 7 7 7 – 8 9 PFO Closure Versus Medical Therapy
779funnel plot method as well as Egger regression asymme-
try testing (3). In case of significant publication bias, we
adjusted the pooled effect estimate with the Duval and
Tweedie nonparametric “trim and fill” method of incor-
porating the estimates theoretically from the missing
studies (4).
Due to a relatively small number of RNE in each study,
the data were assumed to follow a Poisson distribution. For
each study, a 95% confidence interval (CI) estimate for
RNE was computed with Poisson tables. Pooled incidence
rates for the transcatheter closure arm or the medical
therapy arm were calculated with the respective single-arm
studies and by splitting the 2 arms of the comparative
studies and including them in the respective groups. The
pooled incidence rates for the RNE and composite compli-
cation rates were expressed as events/100 person-years (PY),
whereas individual complication rates were more appropri-
ately expressed as event/100 patients followed. The com-
parative estimates were derived only from the studies, which
reported direct comparison of the transcatheter closure and
medical therapy. Odds ratios, relative risk (RR), and/or risk
differences (RD) were used to report pooled estimates for
various comparisons. Meta-regression analysis was con-
ducted to determine the difference in RNE rates between
the 2 strategies after adjusting for age, sex, and presence of
ASA. The meta-analysis has been reported in accordance
with the Metaanalysis of Observational Studies in Epide-
miology guidelines (5).
Results
Study population. The search strategy retrieved 1,056 title
abstracts for review. Of these 1,056 title abstracts, 257
full-text articles were retrieved and reviewed in detail (Fig. 1).
Figure 1. Flow Diagram Demonstrating Selection of Studies for
Meta-Analysis
ASD  atrial septal defect; PFO  patent foramen ovale; RNE  recurrent
neurological event.Data for RNE after transcatheter closure and medical
therapy were derived from 39 studies with 8,185 patients
and 19 studies with 2,142 patients, respectively (6–53). Of
these, 10 studies with 1,886 patients reported comparison of
the 2 treatment modalities and were included for pooled
comparative analysis (10,14,18,20,22,23,31,37,41,42). The
distribution of patients in different study groups, along with
their baseline characteristics, is demonstrated in Table 1.
Because there are no validated scales for assessment of quality
of prospective case series, we assessed the quality on the basis
of selection characteristics, ascertainment of outcome, and loss
to follow-up. For comparative studies, comparability of cohorts
was assessed on the basis of differences in baseline character-
istics. Due to the inherent differences in the selection as well as
baseline characteristics of these cohorts, we refrained from
making firm conclusions on the basis of the pooled estimates
derived from these comparative studies. The individual com-
ponents of each of these quality parameters are demonstrated
in Online Table 1. Although administration of antiplatelet
and/or anticoagulant therapy was observed to be a common
practice after device closure, the regimen and the dosage varied
considerably across the studies (Online Table 2). Low-dose
aspirin with or without clopidogrel was the most common
regimen used for thromboprophylaxis in the immediate post-
closure period.
RNE. Figure 2 demonstrates the pooled incidence of RNE
among the transcatheter PFO closure and the medical
therapy arms. The pooled incidence of RNE/100 PY among
the transcatheter closure was estimated as 0.76 (95% CI:
0.48 to 1.05) events as compared with 4.39 (95% CI: 3.20 to
5.59) events in the medical therapy arm. With comparative
studies, we calculated that there was a significantly reduced
number of RNE among patients undergoing transcatheter
closure as compared with those managed medically (RR:
0.25 [95% CI: 0.11 to 0.58]) (Fig. 2B).
Figure 3 demonstrates the comparison of RNE among
the patients managed medically with anticoagulants versus
antiplatelet medications. The incidence of RNE/100 PY in
the antiplatelet arm was estimated as 4.2 (95% CI: 2.9 to
5.4) events as compared with 2.2 (95% CI: 1.1 to 3.4) events
observed among patients receiving anticoagulation. Pooled
analysis of the comparative studies yielded significantly
lower risk of RNE among patients receiving anticoagulation
as compared with those receiving antiplatelet medications
(RR: 0.58 [95% CI: 0.41 to 0.82]).
Device-related complications. Table 2 demonstrates the
complications encountered in the post-procedural and
follow-up period in the 2 study arms. The composite
complication rate/100 PY in the transcatheter closure and
the medical management arm was estimated as 4.1 (95% CI:
3.2 to 5.0) events and 0.4 (95% CI: 0 to 0.9) events,
respectively. Transcatheter closures have been associated
with a high rate of procedural success (failure rate: 0.01%).
The reintervention rate in the follow-up period was esti-
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 7 , 2 0 1 2
J U L Y 2 0 1 2 : 7 7 7 – 8 9
Agarwal et al.
PFO Closure Versus Medical Therapy
780mated as 0.9% (95% CI: 0.2 to 1.6). The most frequent
complication after transcatheter closure was reported to be
atrial arrhythmias (incidence: 3.9% [95% CI: 2.7 to 6.1]).
The incidence of device-related thrombosis was estimated
as 0.6% (95% CI: 0.3 to 0.9). The proportion of patients
with complications requiring surgical intervention was esti-
mated as 0.3% (95% CI: 0.1 to 0.5). The rate of bleeding
complications in the transcatheter closure arm was esti-
Table 1. Baseline Characteristics
Author/Year (Ref. #) n
Mean
Follow-Up
(Yrs) Devices Used
Ag
(mea
Transcatheter closure
Sievert/2001 (6) 281 1.0 1, 3, 4, 7, 8, 9, 10, 11 46.8
Braun/2002 (7) 276 1.3 10 45.3
Martı´n/2002 (8) 110 2.3 1, 8 47
Onorato/2003 (9) 256 1.6 1, 4, 10 48
Windecker/2004 (10) 150 2.3 1, 2, 8, 10, 11 50
Braun/2004 (11) 130 1.8* 1, 3 45.5
Knebel/2004 (12) 113 1.4 1, 2, 7 46.8
Alameddine/2004 (13) 272 0.1 2, 3 51
Schuchlenz/2005 (14) 167 2.8 1, 2, 3, 7 44
Post/2005 (15) 112 1.9* 1, 3, 4, 10 52.1
Tande/2005 (16) 120 1.1 1, 2, 6
Billinger/2006 (17) 128 1.8 4 50
Harrer/2006 (18) 34 2.1 1, 2, 7, 8, 9, 10 49.5
Giardini/2006 (19) 131 1.9 1, 2, 4 45
Thanopoulos/2006 (20) 48 2.0 1 43
Kiblawi/2006 (21) 456 1.5 2 51.1
Cerrato/2006 (22) 21 2.6 NR 45
Casaubon/2007 (23) 47 2.7 1, 2 43
Slavin/2007 (24) 131 2.5 1, 2 52.4
Harms/2007 (25) 237 1.6 1, 2 53
Egred/2007 (26) 109 1.4 1, 3 45.3
Dubiel/2008 (27) 125 3.3 1, 2, 3, 5, 10 48.3
Luermans/2008 (28) 430 0.8* 12 50.7
Spies/2008 (29) 1,055 1.5* 1–9, 11–14 50.4
Taffe/2008 (30) 660 0.1 1, 3, 4 49.3
van de Wyngaert/2008 (31) 66 3.7 1, 3, 4, 10 41.5
Balbi/2008 (32) 128 2.7 1, 4, 6
Kutty/2008 (33) 216 2.1 2 50
Fischer/2008 (34) 154 2.2 3 43.9
Wahl/2009 (35) 620 3.0 1 51
Sievert/2009 (36) 144 0.5 15 46
Weimar/2009 (37) 117 2.4 NR 46
von Bardeleben/2009 (38) 357 3.8 1, 3, 4 51
Greutmann/2009 (39) 135 0.5 1 51
Presbitero/2009 (40) 216 1.6 1, 4, 5, 6 52.5
Lee/2010 (41) 22 2.9 1, 2 41
Paciaroni/2011 (42) 121 2.0 1, 3, 10, 15 43.4
Thaman/2011 (43) 166 1.4 1, 4, 5 47
Hammerstingl/2011 (44) 124 6.7 1, 2, 4, 5 49.2mated as 1.7% (95% CI: 1.1 to 2.4). In comparison, the rateof bleeding complications in the medical therapy arm was
estimated as 1.1% (95% CI: 0 to 2.5).
To determine the impact of improvement of procedural
technique and device design, we analyzed the complication
rate in the early period (2001 to 2005) and the late period
(2006 to 2011) separately. Although there was a trend
toward a reduction in the complication rate from the early
period to the late period in both study groups, this difference
)
D) Men ASA Hypertension Hyperlipidemia Smoking Diabetes
2 — 23% — — — —
7) 53% 22% 18% — — 3%
0 53% 15% 16% 26% 20% —
0 41% 41% — — — —
53% 25% 28% — 33% 4%
8 58% 25% 20% 9.2% 31% 6.1%
0 — 31% — — — —
2 47% 33% — — — —
0 53% 25% 17% 12.6% 5.4% 6.6%
5 56.3% 18.8% — — — —
42.5% 34.2% 40% 53.3% 34.2% 14.2%
51.6% 29.7% —
5 44.1% 32.4% 17.6% 8.8% 29.4% 2.9%
0 51.9% 51.1% — — — —
0 56.3% 27.1% 12.5% 25% 12.5% 4.2%
5 — — — — — —
5 — 33.3% — — — —
53.2% 29.8% 6.4% 17% 29.8% 4.3%
1 50.4% 11.5% 29.8% 34.4% 15.3% 10.7%
48.1% 32.1% 43.0% 37.1% — —
64.2% — — — — —
4 59.2% 50.4% — — — —
53.7% 44.9% — — — —
51.4% 40.5% 20.9% 20.9% 11.1% 7.2%
9 55.2% 36.4% 34.5% — — 4.8%
53% 51.5% 6% 16.7% — —
49.2% 22.7% 19.5% 25.8% 18% 7.8%
49.5% — 30.1% — 22.2% —
5 61% 37% 24.7% 26% 26% 0.6%
60.8% 33.4% 31.9% — 30.3% 4.2%
54.9% 18.1% — — — —
62.4% 29.1% 34.2% — — 7.7%
59.1% 28.6% 41.5% 45.9% 34.7% 6.7%
57.8% 60.7% 27.4% 39.3% 22.2% 2.2%
5 54.6% 12% — — — —
68.2% 4.5% 9% 27.2% 36.4% 0
48.8% 62% 19.8% 19% 27.3% 4.1%
48.2% 27.1% 22.9% 19.9% 24.7% 22.9%
3 46.8% 54.8% 40.3% 21.8% 50% 4.8%
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781isons). In the transcatheter closure arm, there was a small
nonsignificant reduction in the incidence of perforation,
device-related thrombosis, air embolism, bleeding compli-
cations, mortality, and residual shunting in the late period
compared with the early period. In the medical therapy arm,
there was a trend toward reduction in bleeding complica-
tions as well as mortality in the late period compared with
the early period.
Table 3 demonstrates the rates of RNE and major
omplications across the most common devices used in the
ncluded studies. Amplatzer (AGA Medical Corporation,
olden Valley, Minnesota) was the most common device
sed (38.5%), followed by the CardioSEAL (NMT Medi-
al, Boston, Massachusetts) device (18.6%). The rates of
NE ranged from 0.1 to 1.7 events/100 PY across the
arious device types. Atrial arrhythmias were most fre-
uently encountered with CardioSEAL (10.2/100 PY) and
tarflex (NMT Medical) devices (9.0/100 PY) and least
ommonly with Amplatzer and Helex (Gore Medical,
lagstaff, Arizona) devices. Among all the devices used,
evice-related thrombosis was most commonly encountered
ith the Starflex (3.3/100 PY) and the PFO Star device
2.8/100 PY). Helex devices seemed to have the highest
ates of medium- to long-term (14.8%) residual shunting
nd a slightly higher risk of device embolization or malpo-
Table 1. Continued
Author/Year (Ref. #) n
Mean
Follow-Up
(Yrs) Devices Used
Age (y
(mean 
Medical therapy
Hanna/1994 (45) 16 2.3 — 43*
Mas/1995 (46) 107 1.9 — 39.4
Hausmann/1995 (47) 51 4.9 — 46.1
Bougousslavsky/1996 (48) 140 3.0 — 44
Cujec/1999 (49) 52 3.6 — 38
De Castro/2000 (50) 74 2.6* — 53
Mas/2001 (51) 277 3.2 — 40.3
Anzola/2003 (52) 59 5.1 — 45.3
Windecker/2004 (10) 158 2.4 — 50.7
Schuchlenz/2005 (14) 113 2.6 — 47.7
Harrer/2006 (18) 83 4.6 — 52.5
Thanopoulos/2006 (20) 44 2.0 — 40
Cerrato/2006 (22) 59 4.7 — 45
Casaubon/2007 (23) 61 2.7 — 50.3
van de Wyngaert/2008 (31) 66 2.7 — 41.5
Serena/2008 (53) 297 1.9 — 53.2
Weimar/2009 (37) 234 2.4 — 57
Lee/2010 (41) 159 3.5* — 53
Paciaroni/2011 (42) 117 2.0 — 40.9
Device key: 1: Amplatzer; 2: CardioSEAL; 3: Starflex; 4: Helex; 5: Premere; 6: Cardia; 7: Rashkind; 8: Sid
*Median reported.
ASA atrial septal aneurysm; NR not reported.ition (1.4/100 PY) as compared with other device types. dPFO morphology. In the transcatheter closure arm, the
ncidence of RNE/100 PY among patients with PFO alone
ersus those with PFO and ASA was estimated as 0.3 (95%
I: 0.1 to 0.6) events and 0.4 (95% CI: 0.1 to 1.0) events,
espectively. In the medical management arm, the respective
ncidence of RNE/100 PY among patients with PFO alone
nd PFO and ASA was estimated as 2.4 (95% CI: 0.9 to
.0) events and 6.2 (95% CI: 2.8 to 9.6) events. In the
ranscatheter closure arm, there was no significant difference
bserved in RNE between the 2 morphological groups (RD: 0
95% CI: 0.01 to 0.01]). However, in the medical manage-
ent arm, there was significantly increased RNE observed in
atients with PFO and ASA as compared with patients with
FO alone (RD: 0.03 [95% CI: 0.01 to 0.05]) (Fig. 4).
Figure 5 demonstrates the effect of increasing proportion
f a large pre-treatment shunt upon incidence of RNE in
oth study arms. With an increasing proportion of patients
ith large shunts, a significant increase was lacking in the
ate of RNE after transcatheter PFO closure. Although
here was no apparent trend toward increasing RNE with
ncreasing proportion of patients with large shunts in the
edical arm, the rate of RNE in the medical arm was
ignificantly higher than the transcatheter arm in corre-
ponding shunt categories.
Effect of age. Across the published data, studies used
Men ASA Hypertension Hyperlipidemia Smoking Diabetes
69% 38% — — — —
50% 35.5% 7% 21% 48% 3%
61% 7.8% — — — —
60% 25% 14% 14% 31% 4%
60% 23% — — — —
— 36% — — — —
53% 22% 9% 12% 44% 3%
39% 12% 31% 12% 25% —
58.9% 20.8% 32.9% 30.4% 32.9% 9.5%
54.9% 23.9% 21.2% 23.9% 19.5% 7.9%
63.9% 22.9% 27.7% 6% 18.1% 4.8%
47.8% 22.7% 27.0% 29.5% 25% 8.3%
— 23.7% — — — —
54.1% 16.4% 24.6% 29.5% 41% 6.6%
53% 51.5% 6% 16.7% — —
62% 38.4% 27.6% — 33% 6.4%
65.8% 20.1% 48.3% 14.1% — —
73.6% 11.3% 51.6% 24.5% 36.5% 17%
50.4% 41% 17.1% 19.7% 32.5% 0
ASDOS; 10: PFOstar; 11: Angelwings; 12 Intrasept; 13: Atriasept; 14: Occlutech; 15: Radiofrequency.rs)
SD)
10.5
13.7
14
11.0
14.0

13
13.5
12.7
15.4
12
13.5


14.8

13
10.3
eris; 9:ifferent cutoffs for defining “old” versus “young” popula-
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782tions. For this subgroup analysis, we used a maximum age of
60 years to define the “young” subgroup. The data for this
subgroup analysis was derived from 6 studies with trans-
catheter closure (8,21,29,32,37,38) and 2 studies with med-
ical management (37,53). There was no significant differ-
ence in the risk of RNE between the old and the young
Figure 2. Incidence of Recurrent Neurological Events in the 2 Study Group
(A) Incidence (per 100 patient-years) of recurrent neurological events in the m
cation. (B) Forest plot comparing the risk of recurrent neurological events bet
studies. CI  conﬁdence interval; RR  relative risk.subgroups in the transcatheter closure arm (RR: 1.28 [95% mCI: 0.77 to 2.14]). However, in the medically managed arm,
there was a significantly higher risk of RNE in the older
subgroup as compared with the younger subgroup (RR: 3.27
[95% CI: 1.48 to 7.22]).
Effect of thrombophilia. Due to significant paucity of arti-
les studying the effect of thrombophilia on the optimal
management arm and transcatheter closure arm stratiﬁed by year of publi-
the transcatheter closure and medical management arm in comparatives
edical
weenanagement strategy for stroke prevention due to PTE
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783from PFO, we included all studies, regardless of the sample
size for this particular subgroup analysis. Comparison of
outcomes after transcatheter closure of PFO among patients
with or without hypercoagulable thrombophilia was per-
formed with 9 observational studies (16,19,24,54–59). The
incidence of RNE/100 PY among the patients with throm-
bophilia undergoing transcatheter PFO closure was esti-
mated as 0.3 (95% CI: 0 to 3.2) events as compared with 1.3
(95% CI: 0 to 2.9) events in patients without thrombophilia.
Pooled analysis of comparative estimates failed to reveal any
significant difference in RNE between the 2 subgroups
(RD: 0 [95% CI: 0.04 to 0.03]).
Residual shunting after transcatheter closure. Among the
patients undergoing transcatheter PFO closure, the inci-
dence of residual shunt in the immediate post-procedure
period was estimated as 25.4% (95% CI: 17.4 to 33.5)
(Table 2). This reduced to an estimated rate of 12.5% (95%
CI: 9.6 to 15.5) in the first year of follow-up. On long-term
follow-up beyond 1 year, this rate further dropped down to
6.3% (95% CI: 0.1 to 18.2) (Table 2].
Figure 6 demonstrates the relationship between RNE and
residual shunting reported in the respective studies.
There was no particular trend noted in the incidence of
RNE with increasing residual shunting reported during
the follow-up period across the analyzed studies. In
addition, we observed that the presence of residual
shunting did not predispose individuals to increased risk
of RNE in the follow-up period. Among the patients
with RNE, the odds of having a residual shunt were
Figure 3. Incidence of Recurrent Neurological Events in the Anticoagulatio
Forest plot comparing the risk of recurrent neurological events between the a
arm. CI  conﬁdence interval; RR  relative risk.significantly lower as compared with the odds of nothaving a residual shunt. This implies that the cause of
RNE in the follow-up period in most individuals might
be actually unrelated to the PFO and its closure.
Meta-regression analysis. Due to significant differences in
he baseline characteristics of the included studies, a
ignificant limitation exists in terms of interpretation of
ooled effect estimates derived from these studies. Meta-
egression analysis was performed to ascertain empirical
ifferences in RNE rates between the 2 groups, after
djustment for mean age, proportion of men in the study,
nd the proportion of patients with ASA. Interaction of
he choice of strategy with each of these variables was
ested individually and collectively, and was not statisti-
ally significant. After adjustment of these variables,
here was a significant reduction of RNE in patients
ndergoing transcatheter closure by 3.5 (95% CI: 2.1 to
.0) events/100 PY, in comparison with those managed
edically (p  0.001).
Publication bias. The effects of publication bias on the
meta-analysis of RNE in the 2 study arms are demonstrated
in Online Figures 1 and 2. We observed that there was no
significant publication bias in the meta-analysis of RNE
after transcatheter closure (p  0.8). However, the meta-
nalysis of RNE after medical therapy has significant
ublication bias (p  0.015), which persisted even after
estricting the studies to include only those with n  100.
With the “fill and trim” method, the corrected effect
estimate for RNE after medical therapy was estimated as 5.0
Antiplatelet Arms
gulation subgroup and antiplatelet subgroup of the medical managementn and
nticoa(95% CI: 3.6 to 6.9) events/100 PY (4).
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784Discussion
Our meta-analysis seeks to understand the available evi-
dence for transcatheter closure in prevention of recurrent
PTE in patients with cryptogenic stroke or TIA, compared
with medical management. The incidence of RNE/100 PY
was estimated at 0.8 and 5.0 events in the transcatheter
closure arm and medical therapy arm, respectively. Meta-
analysis of the small number of comparative studies and the
Table 2. Device-Related Complications Stratified by Treatment Arm
Complication n
Complication
Rate 95% CI
Transcatheter closure
Procedural failures 6,288 0.01% 0–0.2
Effusion or tamponade 3,123 0.3% 0–0.6
Pericardial effusion 3,123 0.1% 0–0.2
Tamponade 3,123 0.2% 0–0.5
Perforation 1792 0.1% 0–0.3
Embolization/malposition 4,724 0.4% 0.2–0.7
Embolization 4,724 0.1% 0–0.3
Malposition 4,724 0.2% 0–0.5
Infection 537 0.1% 0–0.8
Thrombus 7,065 0.6% 0.3–0.9
Atrial arrhythmia 3,496 3.9% 2.7–6.1
Atrial ﬁbrillation 2,635 1.2% 0.7–1.7
Atrial ﬂutter 2,635 0.1% 0–0.2
Air embolism 2,819 0.6% 0.2–1.0
Any bleeding complication 4,546 1.7% 1.1–2.4
Minor hematoma 548 0.8% 0.3–1.3
Major hematoma 548 0.1% 0–0.2
AV ﬁstula 1882 0.2% 0–0.5
Pseudoaneurysm 1,093 0.6% 0.1–1.2
Reintervention 3,017 0.9% 0.2–1.6
Surgical intervention 4,700 0.3% 0.1–0.5
Total death 3,445 0.4% 0.1–0.8
Related death 3,445 0.1% 0–0.3
Unrelated death 3,445 0.3% 0–0.6
Any above complication excluding
unrelated death
7,414 4.1/100 PY 3.2–5.0/100 PY
Residual shunt
Post-procedure 3,440 25.4% 17.4–33.5
12 months or less 4,513 12.5% 9.6–15.5
More than 12 months 406 6.3% 0.1–18.2
Medical therapy
Any bleeding complication 707 1.1% 0–2.5
Minor 707 0.2% 0–0.9
Major 707 0.4% 0–1.4
Total death 929 1.1% 0.1–2.0
Related death 929 0.2% 0–0.7
Unrelated death 929 0.6% 0–1.4
Any above complication excluding
unrelated death
1,234 0.4/100 PY 0–0.9/100 PY
CI confidence interval; PY person-years.meta-regression analysis indicated that there might be a csignificant benefit in reduction of RNE with transcatheter
closure in comparison with the medical therapy alone.
Moreover, in the medical management arm, the risk of
RNE was significantly lower with anticoagulation therapy
compared with antiplatelet therapy.
The device-related complication rate was estimated as 4.1
complications/100 PY in the closure arm. The most com-
mon complication after transcatheter closure was develop-
ment of atrial arrhythmias. The incidence of residual shunt
was 12.5% in the first year of follow-up, which reduced to
6.3% on long-term follow-up beyond 1 year. We did not
observe an increase in the risk of RNE during the follow-up
period among individuals with persistent residual shunt in the
post-procedure period, as compared with those without resid-
ual shunt. Moreover, among individuals with RNE, the odds
of lacking a residual shunt were significantly higher than
having one. This might suggest that a non-PFO-related cause
is often responsible for recurrent thromboembolic events in
individuals who have undergone a transcatheter PFO closure
in the past. In patients with small residual shunts noted on
medium-term follow-up after closure, a trend toward complete
elimination of the shunt has been observed, justifying a
conservative attitude in management of residual shunt, al-
though there are reports of using a second device for manage-
ment of moderate to large residual shunts (60).
Age and transcatheter closure. A strong association has
been demonstrated between cryptogenic stroke and PFO in
patients 55 years of age (61). Due to the greater number
of stroke causes in older patients, the relationship between
cryptogenic stroke and PFO is harder to establish in these
patients (62). We observed a significantly higher rate of RNE
in the older age group managed medically as compared with
the younger age group. However, the rate of RNE was similar
between the older and younger age groups undergoing trans-
catheter closure. This implies that older individuals with
cryptogenic stroke/TIA might derive a benefit of lower rate of
RNE by undergoing transcatheter PFO closure.
Morphology and transcatheter closure. There have been
everal morphological attributes of PFO—such as tunnel
ength, size, presence or absence of multiple fenestrations,
elative thickness of the septal components, ASA, and septal
ypermobility—that have influenced the choice of devices
cross the published data. The prevalence of ASA in the
eneral population has been estimated to range between 1%
n autopsy studies to 2.2% in the echocardiography-based
tudies (63). The presence of PFO with ASA has been
hown to increase the risk of RNE (51). Our meta-
nalysis demonstrated an increased rate of RNE among
ndividuals with PFO and ASA undergoing medical
anagement in comparison with patients with PFO
lone. However, in the transcatheter arm, there was no
ignificant difference in the rate of RNE between the 2
ubgroups, indicating a beneficial effect of transcatheter
losure in preventing recurrent thromboembolic events in
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785patients with PFO and ASA. In addition, we observed
that the rate of RNE was similar, regardless of pre-
treatment shunt size among patients undergoing transcatheter
closure. These data might serve to demonstrate the efficacy of
Table 3. Recurrent Neurological Events and Major Complications Stratified
Amplatzer CardioSEAL
Proportion of total procedure 38.5% 18.6%
Stroke or TIA 0.6 (0.3–0.8) 1.7 (0.1–3.2
Effusion or tamponade 0.2 (0–0.8) 0.1 (0–2.8)
Embolization/malposition 0.1 (0–0.5) 0.3 (0–0.9)
Thrombus 0.1 (0–0.5) 0.6 (0–1.5)
Atrial arrhythmia 1.8 (0.8–2.7) 9.0 (0.2–17.
Bleeding complications 1.6 (0.1–3.1) 2.6 (0.6–3.4
Reintervention 0.8 (0–1.8) 0 (0–3.2)
Surgical intervention 0.2 (0–0.8) 0.4 (0–1.0)
Related death 0 (0–0.3) 0 (0–0.4)
Residual shunt
Post-procedure 17.3 (8.4–26.3) 13.6 (5.4–21.
12 months or less 6.3 (2.5–10.2) 6.2 (0–12.4)
More than 12 months 1.8 (0–5.2) 1.5 (0–4.9)
Values are incidence (95% confidence interval)/100 person years. All major device types have been
TIA transient ischemic attack.
Figure 4. Comparison of Recurrent Neurological Events Between PFO and
Forest plot comparing the risk of recurrent neurological events between the p
and atrial septal aneurysm, stratiﬁed by the treatment arm. RD  risk difference; othtranscatheter closure independent of the pre-closure PFO
morphology and/or functionality.
Thrombophilia and transcatheter closure. It has been sug-
gested that presence of thrombophilia in the presence of
evice Type
PFOStar Starflex Helex
11.0% 9.3% 8.9%
1.6 (0–3.3) 0.9 (0–2.0) 0.1 (0–0.5)
0.1 (0–1.1) 0.1 (0–0.8) 0.5 (0–1.7)
0.7 (0–1.7) 0.6 (0–2.0) 1.4 (0–3.0)
2.8 (1.0–4.7) 3.3 (1.5–5.1) 0 (0–0.7)
6.9 (0–18.7) 10.2 (4.9–15.4) 0.1 (0–8.0)
4.7 (1.0–13.7) 0.2 (0–1.0) 2.0 (0–6.1)
0 (0–2.9) 1.8 (0–7.2) 2.1 (0–4.6)
0.8 (0–2.0) 2.2 (0–4.5) 0 (0–1.7)
0 (0–1.0) 0 (0–1.1) 0 (0–1.4)
46.9 (36.5–57.3) 33.6 (19.1–48.1) 46.1 (23.7–68.5)
11.8 (2.4–21.2) 8.8 (4.8–12.9) 21.3 (1.0–51.7)
— 1.8 (0–3.6) 14.8 (0–48.5)
nted in this table.
ith ASA Groups
s with patent foramen ovale only versus patients with patent foramen ovaleby D
)
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786PFO significantly increases the risk of recurrent thrombo-
embolic episodes (19,64). Our meta-analysis demonstrated
that there was no significant difference in the rate of RNE
between patients with or without thrombophilia undergoing
transcatheter closure. This might imply that the transcath-
eter PFO closure helps alleviate the risk of RNE among
patients with thrombophilia to the levels encountered by
those without any hypercoagulable state.
Clinical perspective. Despite over 15,000 closure procedures
eported in the published data, controversy still persists with
egard to indication for transcatheter PFO closure over
edical therapy. There are several ongoing randomized
rials comparing the efficacy of transcatheter PFO closure
ith medical therapy in prevention of recurrent thrombo-
mbolic events; the CLOSURE 1 trial is the only completed
rial (2). Why do we find suggestion of benefit with
bservational studies but were not able to prove that in the
LOSURE 1 trial? There are several interesting points
bout the trial that are worth considering. One, the trial
ncluded patients with stroke and TIA. Two, many recur-
ent strokes reported in the trial were device-related. Three,
he cause of recurrent stroke was not PTE in most patients.
he trial suggested that all patients with neurological
ymptoms and concomitant PFO should not undergo trans-
atheter PFO closure. However, our meta-analysis suggests
hat real-world selection of high-risk patients where PFO
as more likely to be the cause of the stroke is likely to be
more beneficial strategy in successful prevention of RNE
fter transcatheter closure. How would we accomplish this?
eticulous attention to patient selection with detailed
istory and work-up to eliminate other etiologies of stroke
Figure 5. Impact of Pre-Treatment Shunt Size Upon Recurrent Neurologica
Incidence (per 100 person-years) categorized by the proportion of patients with pnd maximizing the likelihood of PTE as an etiology for otroke by detailed evaluation of PFO morphology and
hrombophilia can help identify patients at risk of RNE
econdary to PTE through a PFO. Furthermore, our
eta-analysis clearly suggests that, among patients destined
o medical management, use of anticoagulant therapy is far
uperior to antiplatelet therapy alone for prevention of
NE. Barring definite contraindication to warfarin use,
nticoagulant therapy should be strongly preferred for stroke
revention in medically managed patients who present with
TE.
Study limitations. The choice of medical therapy versus
ranscatheter closure is usually dependent on the preference
f the patient for a particular therapy, allowing a self-selection
ias. Systematic pooling of different observational studies with
ifferent baseline characteristics might induce some impreci-
ion in the results due to heterogeneity. Several studies in-
luded in the meta-analysis have small numbers or have short
ollow-up periods. Due to relative rarity of RNE after trans-
atheter closure, recurrent events are more likely to be observed
n larger study samples with a longer follow-up period.
The present meta-analysis is limited by the possibility
f a strong selection bias, which forms at least 1 rationale
or conducting the study. Several studies might report
rroneous estimates due to inclusion of patients who have
undiagnosed yet unrelated” source of thromboembolism
ather than PTE secondary to PFO (Fig. 7). There exists
chance that the results might be fundamentally skewed
n a nonrandom fashion when comparing one population
transcatheter) to another (medical therapy). Despite
hese limitations, our meta-analysis seeks to clarify an
xtensive and confusing published data by systematic
ts
tment large shunts in the 2 treatment arms. CI  conﬁdence interval.l Evenrganization and aggregation of available information.
n-yea
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 7 , 2 0 1 2 Agarwal et al.
J U L Y 2 0 1 2 : 7 7 7 – 8 9 PFO Closure Versus Medical Therapy
787Conclusive data from the ongoing randomized control
trials would help clarify this question in a more definitive
manner.
Conclusions
Accepting the limitations of this comparative meta-
analysis of observational studies, we observed that trans-
catheter PFO closure was associated with an 84% reduc-
tion in the rate of RNE compared with medical
Figure 6. Effect of Post-Procedure Residual Shunt on Recurrent Neurologic
(A) Incidence of recurrent events stratiﬁed by percent residual shunt reported
thromboembolic event. CI  conﬁdence interval; OR  odds ratio; PY  persomanagement (0.8 events/100 PY compared with 5.0events/100 PY). Comparison of the anticoagulation and
antiplatelet therapy subgroups of the medical arm yielded
a significantly lower risk of RNE in patients treated with
anticoagulants. Device-related complications were en-
countered at the rate of 4.1 events/100 PY, with atrial
arrhythmias being the most frequent complication. The
risk of recurrent thromboembolism did not seem to be
related to presence of residual shunting in the follow-up
period. Significant benefit of transcatheter PFO closure
was apparent in elderly patients, patients with concomi-
nts
dds of presence versus absence of residual shunt in patients with a recurrent
rs.al Eve
. (B) Otant ASA, and patients with thrombophilia.
bolis
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